Literature DB >> 28902734

Incidental Detection of Hepatocellular Carcinoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.

D Patel1, H Loh, K Le, A Stevanovic, R Mansberg.   

Abstract

A 66-year-old man with history of prostate carcinoma underwent Ga-labeled prostate-specific membrane antigen PET/CT for surveillance of rising prostate-specific antigen. Intense tracer uptake was noted in segments 2, 7, and 8 of the liver. The lesions were not FDG avid on F-FDG PET/CT. Further characterization with magnetic resonance cholangiopancreatography with Gd-EOB (Primovist) contrast revealed ill-defined arterially enhancing lesions with central washout in the venous phase. CT-guided core biopsy was performed, and histopathology confirmed well-differentiated hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28902734     DOI: 10.1097/RLU.0000000000001832

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.

Authors:  Qiaomiao Lu; Yu Long; Kevin Fan; Zhiwen Shen; Yongkang Gai; Qingyao Liu; Dawei Jiang; Weibo Cai; Chidan Wan; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-28       Impact factor: 10.057

2.  Cancers and Benign Processes on 68 Ga PSMA PET-CT Imaging Other than Prostate Cancer.

Authors:  Pinar Pelin Ozcan; Mustafa Serdengectı; Zehra Pinar Koc; Yüksel Balcı; Mesut Tek; Murat Bozlu; Erdem Akbay; Vehbi Erçolak
Journal:  World J Nucl Med       Date:  2022-07-05

3.  Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer.

Authors:  Simon Sirtl; Andrei Todica; Harun Ilhan; Michal Zorniak; Peter Bartenstein; Julia Mayerle
Journal:  Diagnostics (Basel)       Date:  2021-01-15

Review 4.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.